Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Big data analysis of nanoscience bibliometrics, patent, and funding data (2000-2019) / / Yuliang Zhao, Hongjun Xiao, and Xingxing He, editors
| Big data analysis of nanoscience bibliometrics, patent, and funding data (2000-2019) / / Yuliang Zhao, Hongjun Xiao, and Xingxing He, editors |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Amsterdam, Netherlands : , : Elsevier B.V., , [2021] |
| Descrizione fisica | 1 online resource (117 pages) |
| Disciplina | 620/.5072 |
| Soggetto topico |
Nanoscience - Research
Nanoscience - Data processing Big data |
| ISBN |
0-323-91312-1
0-323-91311-3 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Scholarly output and academic impact of nanoscience -- The contribution of nanoscience to basic research -- The impact of nanoscience on industry -- Factors that promote the development of nanoscience. |
| Record Nr. | UNINA-9910583322703321 |
| Amsterdam, Netherlands : , : Elsevier B.V., , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Biomedical nanomaterials / / edited by Yuliang Zhao and Youqing Shen
| Biomedical nanomaterials / / edited by Yuliang Zhao and Youqing Shen |
| Pubbl/distr/stampa | Weinheim, Germany : , : Wiley-VCH, , 2016 |
| Descrizione fisica | 1 online resource (501 p.) |
| Disciplina | 610.28 |
| Soggetto topico | Biomedical materials |
| Soggetto genere / forma | Electronic books. |
| ISBN |
3-527-69441-2
3-527-69443-9 3-527-69439-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Title Page; Copyright; Contents; List of Contributors; Chapter 1 Pharmacokinetics and Pharmacodynamics (PK/PD) of Bionanomaterials; 1.1 Introduction; 1.2 Commonly Utilized NMs in Pharmaceutical Research; 1.2.1 Natural NMs; 1.2.1.1 Lipid-Based NMs; 1.2.1.2 Protein-Based NMs; 1.2.1.3 Polysaccharide-Based NMs; 1.2.2 Synthetic NMs; 1.2.2.1 Diversity of Synthetic NMs in Forms; 1.2.2.2 Drug Release Behaviors; 1.2.3 Inorganic NMs; 1.2.4 Other NMs; 1.3 In vivo Biodistribution and the Evolving Targeting Principles for NMs; 1.3.1 Organ Distribution versus Cell-Specific Targeting
1.3.2 Targeting Delivery Strategies1.4 Processing NMs by the Biological Systems; 1.4.1 Anatomic Basis of NMs' in vivo Biodistribution Behavior; 1.4.2 Factors Affecting in vivo Biodistribution of NMs; 1.4.2.1 Size; 1.4.2.2 Zeta Potential; 1.4.2.3 Shape and Deformability; 1.4.2.4 Hydrophilicity and Hydrophobicity; 1.4.3 Metabolism and Elimination of NMs; 1.4.3.1 Common Metabolism; 1.4.3.2 Degradable versus Nondegradable NMs; 1.4.3.3 Free Drug versus Drug Encapsulated by NMs; 1.5 Rational Design of Long-Circulating NMs; 1.5.1 NMs with Optimal Physicochemical Characters 1.5.2 Surface Modification to Improve the Intrinsic Features of NMs1.6 Mathematic Simulation of NM-Mediated Cancer Drug Delivery; 1.6.1 Progress: From Experiment to Simulation; 1.6.2 Compartment Models for PK Assessment of NMs; 1.6.3 Physiologically Based Compartment Models; 1.6.3.1 Protocols of Building a PBPK Model for NMs; 1.6.3.2 Examples; 1.6.4 Brief Summary; 1.7 Experimental PK Data of the Applied NMs; 1.7.1 PK Data of NMs Without Drugs; 1.7.2 PK Differences Between Drugs Encapsulated by Different NMs; 1.7.3 Reciprocal Blood and Tissue PK 1.7.4 PK Differences Between Different Components of the Drug-NM System1.7.5 PK Variations Among Different Routes of Administration; 1.8 Perspectives; 1.8.1 Development of NMs; 1.8.2 Pharmacokinetic Study and Model Development; References; Chapter 2 Targeted Dendrimers for Cancer Diagnosis and Therapy; 2.1 Introduction; 2.2 Targeted Dendrimers for Cancer Therapy; 2.2.1 Low Molecular Weight Ligand-Modified Dendrimers; 2.2.1.1 Folic Acid-Modified Dendrimers; 2.2.1.2 Carbohydrate-Modified Dendrimers; 2.2.1.3 Biotin-Modified Dendrimers; 2.2.1.4 Riboflavin-Modified Dendrimers 2.2.1.5 Estrogen-Modified Dendrimers2.2.2 Macromolecular Ligand-Modified Dendrimers; 2.2.2.1 Antibody-Modified Dendrimers; 2.2.2.2 Transferrin (Tf)- and Lactoferrin (Lf)-Modified Dendrimers; 2.2.2.3 EGF- and Fibroblast Growth Factor (FGF)-Modified Dendrimers; 2.2.2.4 Peptide-Modified Dendrimers; 2.2.2.5 Aptamer-Modified Dendrimers; 2.2.2.6 Hyaluronic Acid (HA)-Modified Dendrimers; 2.2.3 Dual-Targeting Ligand-Modified Dendrimers; 2.3 Targeted Dendrimers for Cancer Diagnosis; 2.3.1 Targeted Dendrimers in CT; 2.3.2 Targeted Dendrimers in SPECT; 2.3.3 Targeted Dendrimers in MRI 2.3.4 Targeted Dendrimers in NIR Fluorescence Imaging |
| Record Nr. | UNINA-9910134853203321 |
| Weinheim, Germany : , : Wiley-VCH, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Biomedical nanomaterials / / edited by Yuliang Zhao and Youqing Shen
| Biomedical nanomaterials / / edited by Yuliang Zhao and Youqing Shen |
| Pubbl/distr/stampa | Weinheim, Germany : , : Wiley-VCH, , 2016 |
| Descrizione fisica | 1 online resource (501 p.) |
| Disciplina | 610.28 |
| Soggetto topico | Biomedical materials |
| ISBN |
3-527-69441-2
3-527-69443-9 3-527-69439-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Title Page; Copyright; Contents; List of Contributors; Chapter 1 Pharmacokinetics and Pharmacodynamics (PK/PD) of Bionanomaterials; 1.1 Introduction; 1.2 Commonly Utilized NMs in Pharmaceutical Research; 1.2.1 Natural NMs; 1.2.1.1 Lipid-Based NMs; 1.2.1.2 Protein-Based NMs; 1.2.1.3 Polysaccharide-Based NMs; 1.2.2 Synthetic NMs; 1.2.2.1 Diversity of Synthetic NMs in Forms; 1.2.2.2 Drug Release Behaviors; 1.2.3 Inorganic NMs; 1.2.4 Other NMs; 1.3 In vivo Biodistribution and the Evolving Targeting Principles for NMs; 1.3.1 Organ Distribution versus Cell-Specific Targeting
1.3.2 Targeting Delivery Strategies1.4 Processing NMs by the Biological Systems; 1.4.1 Anatomic Basis of NMs' in vivo Biodistribution Behavior; 1.4.2 Factors Affecting in vivo Biodistribution of NMs; 1.4.2.1 Size; 1.4.2.2 Zeta Potential; 1.4.2.3 Shape and Deformability; 1.4.2.4 Hydrophilicity and Hydrophobicity; 1.4.3 Metabolism and Elimination of NMs; 1.4.3.1 Common Metabolism; 1.4.3.2 Degradable versus Nondegradable NMs; 1.4.3.3 Free Drug versus Drug Encapsulated by NMs; 1.5 Rational Design of Long-Circulating NMs; 1.5.1 NMs with Optimal Physicochemical Characters 1.5.2 Surface Modification to Improve the Intrinsic Features of NMs1.6 Mathematic Simulation of NM-Mediated Cancer Drug Delivery; 1.6.1 Progress: From Experiment to Simulation; 1.6.2 Compartment Models for PK Assessment of NMs; 1.6.3 Physiologically Based Compartment Models; 1.6.3.1 Protocols of Building a PBPK Model for NMs; 1.6.3.2 Examples; 1.6.4 Brief Summary; 1.7 Experimental PK Data of the Applied NMs; 1.7.1 PK Data of NMs Without Drugs; 1.7.2 PK Differences Between Drugs Encapsulated by Different NMs; 1.7.3 Reciprocal Blood and Tissue PK 1.7.4 PK Differences Between Different Components of the Drug-NM System1.7.5 PK Variations Among Different Routes of Administration; 1.8 Perspectives; 1.8.1 Development of NMs; 1.8.2 Pharmacokinetic Study and Model Development; References; Chapter 2 Targeted Dendrimers for Cancer Diagnosis and Therapy; 2.1 Introduction; 2.2 Targeted Dendrimers for Cancer Therapy; 2.2.1 Low Molecular Weight Ligand-Modified Dendrimers; 2.2.1.1 Folic Acid-Modified Dendrimers; 2.2.1.2 Carbohydrate-Modified Dendrimers; 2.2.1.3 Biotin-Modified Dendrimers; 2.2.1.4 Riboflavin-Modified Dendrimers 2.2.1.5 Estrogen-Modified Dendrimers2.2.2 Macromolecular Ligand-Modified Dendrimers; 2.2.2.1 Antibody-Modified Dendrimers; 2.2.2.2 Transferrin (Tf)- and Lactoferrin (Lf)-Modified Dendrimers; 2.2.2.3 EGF- and Fibroblast Growth Factor (FGF)-Modified Dendrimers; 2.2.2.4 Peptide-Modified Dendrimers; 2.2.2.5 Aptamer-Modified Dendrimers; 2.2.2.6 Hyaluronic Acid (HA)-Modified Dendrimers; 2.2.3 Dual-Targeting Ligand-Modified Dendrimers; 2.3 Targeted Dendrimers for Cancer Diagnosis; 2.3.1 Targeted Dendrimers in CT; 2.3.2 Targeted Dendrimers in SPECT; 2.3.3 Targeted Dendrimers in MRI 2.3.4 Targeted Dendrimers in NIR Fluorescence Imaging |
| Record Nr. | UNINA-9910830907803321 |
| Weinheim, Germany : , : Wiley-VCH, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Toxicology of nanomaterials / / edited by Yuliang Zhao, Zhiyong Zhang, and Weiyue Feng
| Toxicology of nanomaterials / / edited by Yuliang Zhao, Zhiyong Zhang, and Weiyue Feng |
| Pubbl/distr/stampa | Weinheim, Germany : , : Wiley-Vch Verlag GmbH & Co. KGaA, , 2016 |
| Descrizione fisica | 1 online resource (435 p.) |
| Disciplina | 338.476205 |
| Soggetto topico | Nanostructured materials - Toxicology |
| ISBN |
3-527-68915-X
3-527-68913-3 3-527-68912-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Title Page; Copyright; Contents; List of Contributors; Preface; Abbreviations; Chapter 1 Characterization of Nanomaterials in Nanotoxicological Analyses; 1.1 Introduction; 1.2 Size and Morphology of NMs; 1.2.1 Transmission Electron Microscopy (TEM); 1.2.2 Scanning Electron Microscopy (SEM); 1.2.3 Scanning Tunneling Microscopy (STM); 1.2.4 Atomic Force Microscopy (AFM); 1.2.5 Dynamic Light Scattering (DLS); 1.2.6 X-ray Diffraction (XRD); 1.2.7 Small-Angle X-ray Scattering (SAXS); 1.2.8 Brunauer-Emmett-Teller (BET); 1.2.9 Raman Scattering (RS); 1.3 Composition and Structure
1.3.1 Absorption and Emission Spectroscopy1.3.2 Mass Spectrometry (MS); 1.3.3 X-ray Fluorescence Spectrometry (XRF); 1.3.4 Nuclear Magnetic Resonance (NMR); 1.3.5 X-ray Absorption Spectroscopy (XAS); 1.4 Surface Properties; 1.4.1 Surface Area; 1.4.2 Surface Charge; 1.4.3 Surface Composition; 1.4.4 Surface Reactivity; 1.5 Interactions between NMs and Biological Environments; 1.6 Conclusions; References; Chapter 2 Quantitative Analysis of Metal-Based Nanomaterials in Biological Samples Using ICP-MS; 2.1 Introduction; 2.2 ICP-MS: A Power Tool for Element Analysis; 2.2.1 Unique Features of ICP-MS 2.2.2 ICP-MS Hyphenated to Separation Techniques2.3 Single-Particle ICP-MS: Theory and Application; 2.3.1 Basic Theory of SP-ICP-MS; 2.3.2 Applications of SP-ICP-MS; 2.4 Analysis of Nanoparticles by ICP-MS Hyphenate Techniques; 2.4.1 Solution-Based ICP-MS Hyphenated Techniques; 2.4.1.1 Field Flow Fractionation; 2.4.1.2 Hydrodynamic Chromatography; 2.4.1.3 Electrophoresis; 2.4.1.4 Laser Ablation ICP-MS for ENM Analysis; 2.5 Conclusion and Outlook; References; Chapter 3 Stable Isotopic Tracing of Nanomaterials In Vivo; 3.1 Introduction 3.2 Development of Stable Isotope Labeling in Nanotechnology3.3 13C-Labeled Carbon Nanomaterials; 3.3.1 Structure and Formation Mechanisms for Fullerene; 3.3.2 Trace and Quantification In Vivo for Fullerene; 3.3.3 Quantification and Distribution of 13C-CNT and Carbon Particles; 3.3.4 Isotope Effects and Imaging of 13C-CNT; 3.3.5 Structure and Formation of 13C-Enriched Graphene Nanomaterials; 3.4 Metal Stable Isotope Labeled Nanoparticles; 3.4.1 Trace and Quantification of ZnO Nanoparticles in Nanotoxicology and Ecotoxicology 3.4.2 Trace and Quantification of CuO Nanoparticles in Nanotoxicology and Ecotoxicology3.4.3 Other Stable Isotopes for Tracing and Quantifying Nanomaterials In Vivo; 3.4.4 Other Stable Isotopes for the Structure and Reaction of Nanomaterials; 3.5 Summary and Outlook; References; Chapter 4 Radiolabeling of Nanoparticles; 4.1 Introduction; 4.1.1 Radioisotope Production; 4.1.2 Radiolabeling Methods of Nanoparticles; 4.1.2.1 Synthesis of Nanoparticles from Radioactive Precursors; 4.1.2.2 Neutron or Ion-Beam Activation; 4.1.2.3 Isotopic Exchange and Cation Exchange; 4.1.2.4 Physical Absorption 4.1.2.5 Covalent Attachment |
| Record Nr. | UNINA-9910134855303321 |
| Weinheim, Germany : , : Wiley-Vch Verlag GmbH & Co. KGaA, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Toxicology of nanomaterials / / edited by Yuliang Zhao, Zhiyong Zhang, and Weiyue Feng
| Toxicology of nanomaterials / / edited by Yuliang Zhao, Zhiyong Zhang, and Weiyue Feng |
| Pubbl/distr/stampa | Weinheim, Germany : , : Wiley-Vch Verlag GmbH & Co. KGaA, , 2016 |
| Descrizione fisica | 1 online resource (435 p.) |
| Disciplina | 338.476205 |
| Soggetto topico | Nanostructured materials - Toxicology |
| ISBN |
3-527-68915-X
3-527-68913-3 3-527-68912-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Title Page; Copyright; Contents; List of Contributors; Preface; Abbreviations; Chapter 1 Characterization of Nanomaterials in Nanotoxicological Analyses; 1.1 Introduction; 1.2 Size and Morphology of NMs; 1.2.1 Transmission Electron Microscopy (TEM); 1.2.2 Scanning Electron Microscopy (SEM); 1.2.3 Scanning Tunneling Microscopy (STM); 1.2.4 Atomic Force Microscopy (AFM); 1.2.5 Dynamic Light Scattering (DLS); 1.2.6 X-ray Diffraction (XRD); 1.2.7 Small-Angle X-ray Scattering (SAXS); 1.2.8 Brunauer-Emmett-Teller (BET); 1.2.9 Raman Scattering (RS); 1.3 Composition and Structure
1.3.1 Absorption and Emission Spectroscopy1.3.2 Mass Spectrometry (MS); 1.3.3 X-ray Fluorescence Spectrometry (XRF); 1.3.4 Nuclear Magnetic Resonance (NMR); 1.3.5 X-ray Absorption Spectroscopy (XAS); 1.4 Surface Properties; 1.4.1 Surface Area; 1.4.2 Surface Charge; 1.4.3 Surface Composition; 1.4.4 Surface Reactivity; 1.5 Interactions between NMs and Biological Environments; 1.6 Conclusions; References; Chapter 2 Quantitative Analysis of Metal-Based Nanomaterials in Biological Samples Using ICP-MS; 2.1 Introduction; 2.2 ICP-MS: A Power Tool for Element Analysis; 2.2.1 Unique Features of ICP-MS 2.2.2 ICP-MS Hyphenated to Separation Techniques2.3 Single-Particle ICP-MS: Theory and Application; 2.3.1 Basic Theory of SP-ICP-MS; 2.3.2 Applications of SP-ICP-MS; 2.4 Analysis of Nanoparticles by ICP-MS Hyphenate Techniques; 2.4.1 Solution-Based ICP-MS Hyphenated Techniques; 2.4.1.1 Field Flow Fractionation; 2.4.1.2 Hydrodynamic Chromatography; 2.4.1.3 Electrophoresis; 2.4.1.4 Laser Ablation ICP-MS for ENM Analysis; 2.5 Conclusion and Outlook; References; Chapter 3 Stable Isotopic Tracing of Nanomaterials In Vivo; 3.1 Introduction 3.2 Development of Stable Isotope Labeling in Nanotechnology3.3 13C-Labeled Carbon Nanomaterials; 3.3.1 Structure and Formation Mechanisms for Fullerene; 3.3.2 Trace and Quantification In Vivo for Fullerene; 3.3.3 Quantification and Distribution of 13C-CNT and Carbon Particles; 3.3.4 Isotope Effects and Imaging of 13C-CNT; 3.3.5 Structure and Formation of 13C-Enriched Graphene Nanomaterials; 3.4 Metal Stable Isotope Labeled Nanoparticles; 3.4.1 Trace and Quantification of ZnO Nanoparticles in Nanotoxicology and Ecotoxicology 3.4.2 Trace and Quantification of CuO Nanoparticles in Nanotoxicology and Ecotoxicology3.4.3 Other Stable Isotopes for Tracing and Quantifying Nanomaterials In Vivo; 3.4.4 Other Stable Isotopes for the Structure and Reaction of Nanomaterials; 3.5 Summary and Outlook; References; Chapter 4 Radiolabeling of Nanoparticles; 4.1 Introduction; 4.1.1 Radioisotope Production; 4.1.2 Radiolabeling Methods of Nanoparticles; 4.1.2.1 Synthesis of Nanoparticles from Radioactive Precursors; 4.1.2.2 Neutron or Ion-Beam Activation; 4.1.2.3 Isotopic Exchange and Cation Exchange; 4.1.2.4 Physical Absorption 4.1.2.5 Covalent Attachment |
| Record Nr. | UNINA-9910821457903321 |
| Weinheim, Germany : , : Wiley-Vch Verlag GmbH & Co. KGaA, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||